Sutro Biopharma, Inc.

NasdaqGM STRO

Sutro Biopharma, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -80.79%

Sutro Biopharma, Inc. Operating Income Margin is -80.79% for the Trailing 12 Months (TTM) ending September 30, 2024, a 78.37% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Sutro Biopharma, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -373.45%, a -127.13% change year over year.
Sutro Biopharma, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -164.42%, a -10.76% change year over year.
Sutro Biopharma, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -148.45%, a -11.34% change year over year.
Sutro Biopharma, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -133.33%, a -53.21% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqGM: STRO

Sutro Biopharma, Inc.

CEO	Mr. William J. Newell J.D.
IPO Date	Sept. 27, 2018
Location	United States
Headquarters	111 Oyster Point Boulevard
Employees	302
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Key trends

Past 5 years